Overview

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the experimental drug, 177Lu-J591 and see what effects (good and bad) it has on your prostate cancer. Another purpose is to find the highest dose of the drug that can be given without causing severe side effects.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Antibodies